Abstract
Introduction Detection of Mycobacterium tuberculosis (Mtb) in patient-derived bioaerosol is a potential tool to measure source case infectiousness. However, current bioaerosol sampling approaches have reported low detection yields in sputum-positive TB cases. To increase the utility of bioaerosol sampling, we present advances in bioaerosol collection and Mtb identification that improve detection yields.
Methods A previously described Respiratory Aerosol Sampling Chamber (RASC) protocol, or “RASC-1”, was modified to incorporate liquid collection of bioaerosol using a high-flow wet-walled cyclone (RASC-2). Individuals with GeneXpert-positive pulmonary TB were sampled pre-treatment over 60-minutes. Putative Mtb bacilli were detected in collected fluid by fluorescence microscopy utilising DMN-Trehalose. Exhaled air and bioaerosol volumes were estimated using continuous CO2 monitoring and airborne particle counting, respectively. Mtb capture was calculated per exhaled air volume sampled and bioaerosol volume for RASC-1 (n=35) and for RASC-2 (n=21). Empty chamber samples were collected between patients as controls.
Results The optimised RASC-2 protocol sampled a median of 258.4L (IQR: 226.9-273.6) of exhaled air per patient compared with 27.5L (IQR: 23.6-30.3) for RASC-1 (p<0.0001). Bioaerosol volume collection was estimated at 2.3nL (IQR: 1.1-3.6) for RASC-2 compared with 0.08nL (IQR: 0.05-0.10) for RASC-1 (p<0.0001). The detection yield of viable Mtb improved from 43% (median 2 CFU, range: 1-14) to 95% (median 20.5 DMN-Trehalose positive bacilli, range: 2-155). These improvements represent a lowering of the limit of detection in the RASC-2 platform to 0.9 Mtb bacilli per 100L of exhaled air from 3.3 Mtb bacilli per 100L (RASC-1).
Conclusion This study demonstrates that technical improvements in particle collection together with sensitive detection enable rapid quantitation of viable Mtb in bioaerosols of sputum positive TB cases. Increased sampling sensitivity may allow future TB transmission studies to be extended to sputum-negative and subclinical individuals, and suggests the potential utility of bioaerosol measurement for rapid intervention in other airborne infectious diseases.
Introduction
Tuberculosis (TB) remains a serious global public health threat [1]. In 2018, the global incidence was estimated at 10 million with a death toll of 1.5 million [2]. Driving the high burden is on-going transmission of infection, as demonstrated by the 1.1 million cases of childhood TB disease globally. Further evidence for the prominence of transmission comes from molecular epidemiology studies in high-prevalence countries which have highlighted that the majority of TB disease follows from recent Mtb infection [3].
Transmission events are influenced by many factors which relate to the source case, the bacillus, the environment and the host. Fundamental to transmission, however, is the production of aerosolized Mtb: in the absence of aerosol release, no transfer of infectious organisms between individuals can occur. Pioneering experiments performed by Wells and Riley more than 60 years ago utilized the guinea pig as an aerosol sampler, detecting transmission by the demonstration of new infection in the animals [4, 5]. Employing a sampling system with physical separation of patients (source case) and guinea pigs (sampler) led to the confirmation of airborne transmission. Moreover, intricate linking of individual patients to specific guinea pig infections by bacillary resistance patterns and timing of entry and departure from the ward allowed for identification of a minority of highly infectious ‘super-spreaders’. The guinea pig model therefore supported the concepts that infectiousness is highly heterogenous and that small bioaerosol – which arise as a consequence of dehydration of buoyant airborne droplets during “aging” following release into the environment –are primarily responsible for remote transmission [6].
Invaluable though this contribution was to the early understanding of TB transmission, the experimental design was not optimised for sensitive sampling [7]. Minimal sensitivity to Mtb production necessitates sampling multiple patients for days to months for both historical and recent in vivo sampling experiments [8–10].
However, some modern approaches with greater proximity between source case and sampler, single patient sampling and viable organism detection have dramatically improved the overall detection sensitivity. Direct detection has identified Mtb bacilli within only minutes to hours of sampling [11–13], generated individual-level information, and found a greater proportion of emitters.
These sensitive techniques have the potential to efficiently answer questions regarding the transmission potential of patient sub-groups and test strategies for transmission mitigation. Further sensitivity improvement may allow investigation of Mtb-containing droplet release from patients across the TB disease spectrum, including sputum smear-negative cases, HIV-coinfected and even subclinical TB cases. Sensitive sampling combined with quantitative forms of detection also provide an infectivity measure. Such a measure could be applied longitudinally to those receiving chemotherapy to more accurately establish time to bioaerosol sterilisation with direct clinical application.
We describe a direct bioaerosol sampling device designed to collect aged aerosol. We have attempted to optimise key components necessary to maximise detection yield through an iterative re-design process. Preliminary results of sampling from both healthy controls and individuals with newly diagnosed pulmonary TB are also presented.
Materials and Methods
The Respiratory Aerosol Sampling Chamber (RASC) is an enclosed, clean room optimised for the sampling of aged bioaerosol from a single individual during a 60-minute period of natural respiratory activity. A previous description of the RASC design, “RASC-1”, has been published [14] in addition to results from a 35-patient pulmonary TB sampling study [11]. The apparatus and sampling protocols employed for those initial studies is referred to throughout this report as “RASC-1”. The current study describes several design modifications, informed by an iterative series of experiments, which have refined the apparatus and sampling protocol while maintaining the basic structure of the chamber. This new version is referred to as “RASC-2”.
Sample Collection
RASC-1 included an array of aerosol sample collection instruments operated consecutively at the peak of chamber air contamination. This included polycarbonate, gelatin and felt filters, Dekati and Andersen impactors, and a cyclone collector. The flow rates (chamber outflow) varied between instruments, subject to device specifications. Both impactors and the polycarbonate and gelatin filters sampled with flow rates of 20-30 L/min, whereas the felt filter and the cyclone collector sampled with higher flow rates: 300 and 250 L/min, respectively. Results yielded no positive samples from the felt or gelatin filters. For the rest, no sampling instruments demonstrated significantly higher yield per unit of exhaled air sampled. Therefore, to maximize the exhaled air volume sampled, the sample collection process was simplified to a single cyclone collector.
Cyclone Collector
A high-efficiency cyclone collector (Coriolis μ air sampler, Bertin, Montigny le Bretonneux, France) was used for RASC-2 to collect airborne bioaerosol into 5-10 mL of sterile phosphate-buffered saline (PBS) solution. Mounted within the chamber, the air enters the conical collector through a tangential nozzle. The high flow rate of 250 L/min generates a liquid cyclone and particle inertia leads to deposition of bioaerosol from the airstream onto the wet wall with a high collection efficiency. Collection into liquid has the advantage of minimizing particle bounce, improving the recovery of viable Mtb bacilli and maximizing the air volume sampled over time.
Sampling Protocol
The experimental protocol was modified to continuous sampling of the chamber air via the single high-flow (250 L/min) cyclone collector. This replaces the sequential sampling phases of the RASC-1 protocol. Consequently, there is a lowering of the CO2 set-point throughout the protocol and improved regulation of chamber humidity and temperature, illustrated by the CO2 traces in Figure 1. This effect primarily maximizes the air volume sampled by reducing the loss of exhaled air at the end of the study protocol. There is an added benefit of improved thermal comfort for participants.
Differing example CO2 traces for the two sampling protocols (A) RASC-1: initial contamination and short, steady-state sampling (median 3800 PPM CO2). (B) RASC-2: continuous sampling with a lower steady-state (median 1600 PPM CO2).
Mtb Detection
Liquid specimen collection facilitates sample concentration via centrifugation and the application of culture-independent detection techniques. For the RASC-2 protocol, the centrifuged bioaerosol sample pellet was incubated with a novel solvatochromic trehalose analog, DMN-Trehalose, which was incorporated into the cell walls of metabolically active mycobacteria, and subsequently yielding high fluorescence intensity detectable by a fluorescence microscope [15]. Each participant sample was added to a microwell device (Edge Technologies, USA) containing an array of 1600 nanowells measuring 50 × 50 μm. This generated multiple discrete microenvironments for Mtb detection and avoided overgrowth of contaminants affecting the whole sample [16]. Fluorescent microscopy employed a skilled operator to distinguish Mtb on the basis of bacillus morphology and specific staining patterns.
CO2 and Bioaerosol Monitoring
Continuous CO2 and aerodynamic particle monitoring of the chamber air was performed in both sampling protocols, RASC-1 and RASC-2. Estimates of captured Mtb bacilli per unit volume of exhaled air and per unit volume of respiratory bioaerosol were calculated using the method described in the previous (RASC-1) study [12].
Study Participants
All recruited participants were residents from two informal peri-urban settlements outside Cape Town and in close proximity to the study site. Eligible candidates were those with GeneXpert-positive sputum without evidence of drug resistance. Bioaerosol sampling was performed before initiation of anti-tuberculous therapy, as per the approved Ethics protocol (see below). The empty chamber was sampled between human participants to serve as chamber decontamination controls. Baseline patient data were collected from the clinical records and a chest X-ray was taken approximately seven days after the start of treatment. The presence of lung cavitation was scored by one of the authors (BP) based on the chest X-ray and this score was compared to a radiologist report for agreement.
Statistical Analysis
The performance of the RASC-2 protocol was compared with the original RASC-1 design in terms of the exhaled air volume and bioaerosol volume sampled and Mtb bacilli captured. Comparison between the protocols was made with a Wilcoxon rank sum test. Statistical analyses were performed using R Core Team (2019).
Ethical statement
The patient studies are covered by two separate ethics approvals from the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee (HREC/REF: 680/2013; HREC/REF: 529/2019). Each patient provided written informed consent prior to participation in the study, including consent to publication of the clinical and demographic details.
Results
Patient Characteristics
Individuals were consecutively recruited from the same two communities. The RASC-1 protocol was implemented over the time period 2015 to 2017 and RASC-2 from 2018 to 2019. Table 1 compares basic clinical and demographic characteristics, confirming broad equivalence between patients sampled by the two protocols.
Comparison of baseline patient characteristics between RASC-1 and RASC-2.
RASC Comparison
The two RASC designs were compared using indicators of sampling efficiency (Fig. 2A and 2B) and numbers of Mtb bacilli captured (Fig. 2C). The sampled volume of exhaled air was calculated using continuous CO2 measurement to determine exhaled air proportion in chamber air during device sampling. Similarly, chamber bioaerosol concentration was determined by particle counting and volume calculation with the assumption that bioaerosol are spherical. Captured bioaerosol volume was estimated by assuming completely efficient sampling of this concentration. Both these methods have been described previously [11].
Comparative efficiencies of RASC-1 versus RASC-2 in capture of exhaled air (A), collection of bioaerosol volume (B), and capture of Mtb organisms (C). Note that numbers in (C) were determined by colony forming units (RASC-1) and DMN-Trehalose-positive organisms identified using fluorescence microscopy (RASC-2).
RASC Decontamination
As mentioned previously [14], the highly sensitive Mtb detection methodology used in RASC-2 is vulnerable to contamination owing to incomplete sterilization of the chamber. To control for this risk, patient sampling was interspersed with empty RASC sampling. Detected organisms in the control samples suggested a small degree of contamination. Figure 3 demonstrates the different bacillary counts for patient sampling and empty RASC sampling. Control samples remained negative after modification of the collector design and high concentration ozone sterilization of the RASC.
Comparison of total bacillary counts following RASC-2 sampling of sputum GeneXpert-positive TB patients (n=21) and the inter-patient empty booth RASC sampling controls (n=22). P<0.0001.
Limit of Detection
A bacillary count per unit volume of exhaled air was calculated and compared between the two sampling protocols. Figure 4 illustrates the range of detectable concentrations across the sampled populations. Notably, by combining the design improvements, the limit of detection has been lowered from approximately 3.3 bacilli per 100 L exhaled air to 0.9 bacillus per 100 L.
Mtb bacillary counts per 100 L exhaled air for RASC-1 versus RASC-2. Sampled individuals not yielding detectable Mtb bacilli are illustrated by points on the x-axis.
Discussion
This study has shown that, by optimising both bioaerosol collection and Mtb detection, a majority of newly diagnosed GeneXpert sputum positive TB patients can be shown to exhale viable Mtb organisms. The increased numbers of Mtb organisms captured by RASC-2 compared with RASC-1 were associated with an approximate 1 log10 increase in exhaled air sampled and bioaerosol particle volume collected. This is not explained by demographic and clinical characteristics which were broadly equivalent between the patients sampled by the different methods. The resulting lowered limit of detection enabled identification of putative Mtb organisms in 95% of patients whose bacillary concentrations varied over a 2 log10 range from 1 to 100 per 100 L exhaled air. The proportion of patients identified with Mtb positive bioaerosols is therefore a function of lower level of detection. However, exhaled particle volumes varied markedly between individuals, suggesting that infectivity is likely to be impacted by both Mtb concentration of lung fluids and individual bioaerosol particle production.
The current study sampled newly diagnosed TB patients while seated in a small personalized clean room with normal respiration and spontaneous coughing over 60-minutes. Collected bioaerosol were those which remained airborne in the RASC and, at time of collection, were predominantly in the 1-5 μm diameter range. Consistent with prior observations [6], these are the particles thought most likely to reach the peripheral lungs of susceptible individuals sharing an indoor location [17]. It is also probable that these bioaerosols containing viable Mtb organisms might be indicative of a wide range of source infectivity. The investigation of Mtb production and, consequently, potential infectivity during various respiratory manoeuvres is under current investigation in our laboratory.
The sensitive detection of individual Mtb organisms, with DMN-Trehalose staining and subsequent fluorescence microscopy analysis, requires a high degree of sterility to exclude contamination during sampling and isolation. After detailed analysis of the platform and collection equipment, we noted that the wet-walled cyclone contained a dead space which was a potential reservoir for live Mtb cells. Therefore, the device was modified to enable dismantling and autoclaving. The very low numbers of Mtb organisms detected during empty booth sampling could also have resulted from the release of trapped Mtb organisms by the negative pressure inducing retrograde airflow across the exit HEPA filter. Reassuringly, following modification of the collector and the application of combined dry vapour hydrogen peroxide and ozone treatments of the RASC after use, the empty booth controls remained negative.
Conclusion
The development of a sensitive and reproducible measure of Mtb in exhaled bioaerosols has enabled the demonstration of a wide range of potential infectivity of newly diagnosed TB patients. Bioaerosol assays may offer a useful adjunct to TB transmission studies, enabling demonstration of infectivity of sputum negative individuals and the effect of specific chemotherapies on infectivity. Moreover, the protocols and equipment described here suggest the potential application of this technology to other airborne infectious diseases, especially where rapid interventions such as containment and quarantine are required to curb outbreaks [18].
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article.
